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Corneal blindness caused by limbal stem cell deficiency (LSCD) is a prevailing disorder worldwide.
Clinical outcomes for LSCD therapy using amniotic membrane (AM) are unpredictable. Hydrogels can
eliminate limitations of standard therapy for LSCD, because they present all the advantages of AM (i.e.
biocompatibility, inertness and a biodegradable structure) but unlike AM, they are structurally uniform
and can be easily manipulated to alter mechanical and physical properties. Hydrogels can be delivered
with minimum trauma to the ocular surface and do not require extensive serological screening before
clinical application. The hydrogel structure is also amenable to modifications which direct stem cell fate.
In this focussed review we highlight hydrogels as biomaterial substrates which may replace and/or
complement AM in the treatment of LSCD.An overview of LSCD therapy
Damage to the outer limbal region of the cornea due to chemical
(e.g. acid and alkali burns) and mechanical (e.g. extended contact
lens wear) injuries, congenital disorders (e.g. Stevens Johnson
syndrome) or bacterial and viral infections, causes destruction
and depletion of resident adult stem cells [1–5]. LSCD is mani-
fested by conjunctival and epithelial ingrowth, vascularisation,
chronic inflammation, recurrent erosions, persistent ulcers,
destruction of the basement membrane (BM) and fibrous tissue
ingrowth [2–5]. These pathologies lead to severe functional
impairment of the cornea and clinical symptoms include irrita-
tion, epiphora, blepharospasms, photophobia, pain and decreased
vision [2–5]. Consequently, disruptions in renewal of the corneal
epithelium occur (Fig. 1), which ultimately leads to blindness, and
this is complicated by scarring, inflammation, and the invasion of
conjunctival tissue [2–5].
A diverse range of clinical methodologies, presenting inherent
benefits and limitations, are currently available for treating LSCD
[2–10]. Accurate diagnosis of the extent of LSCD (partial or total) is
crucial for the planning of effective strategies to treat this condi-
tion. Variations in the severity of LSCD, however, indicate that the
application of one single treatment type will not be sufficient forCorresponding author: Connon, C.J. (c.j.connon@rdg.ac.uk)
1359-6446/06  2012 Elsevier Ltd. http://dx.doi.org/10.1016/j.drudis.2012.07.012Open access under CC BY license.all indications of this disorder. We will therefore present a concise,
critical evaluation of the evolution of LSCD therapy to appreciate
the range of treatment modalities for this disorder; we refer readers
to a more comprehensive review by Tseng et al. [5] summarising
treatments for this condition.
The basis for LSCD therapy is the transplantation of progenitor
limbal epithelial cells (LEC) into the damaged cornea. The founda-
tions of modern treatment approaches for LSCD were laid when a
surgical procedure using autologous conjunctival limbal autografts
for contralateral cases of this condition was described [3]. This
procedure restored corneal epithelial phenotype and reduced levels
of goblet cells in the recipient cornea. Therapy for bilateral LSCD was
subsequently performed with the transplantation of limbal allo-
grafts from cadavers, and was demonstrated as a viable strategy for
reconstruction of corneal surfaces that had undergone bilateral
diffuse destruction, with the loss of limbal stem cells (LSC) [4].
Therapy for LSCD progressed with the use of amniotic membrane
(AM). AM alone was demonstrated as sufficient to treat partial (i.e.
less than 360 degree damage to limbal tissue) LSCD [6], and AM
without a limbal allograft or autograft has proven successful therapy
for ocular damage as severe as chemical burns [6].
The main clinical benefits of AM include the ability to promote
epithelialisation [6], reduce pain and scarring [7], and minimise
inflammation [8]. The effectiveness of this biological substrate for www.drugdiscoverytoday.com 79
REVIEWS Drug Discovery Today  Volume 18, Numbers 1–2  January 2013
Peripheral
cornea
Conjunctiva
Limbus
Terminally differentiated cell
Transient amplifying cell
Limbal epithelial stem cell
Cornea
Drug Discovery Today 
FIGURE 1
The limbal stem cell niche. Corneal stem cells reside in the limbus at the
corneoscleral junction between the conjunctiva and the cornea. Epithelial
stem cells in the basal region of the limbus regenerate the corneal surface by
differentiating into transient amplifying epithelial cells, which give rise to
terminally differentiated epithelial cells that populate the suprabasal and
superficial layers of the cornea. Damage to the limbal stem cell niche results
in LSCD, disrupting regeneration of the corneal epithelium.
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to AM becoming the scaffold of choice for ex vivo expansion of
LEC, a technique that eliminates the need for removing the limbus
from a healthy eye [9]. Methodology for the cultivation of LEC on
AM to preserve their stem phenotype and encourage proliferation
and stratification continues to be rigorously investigated [5,10].
The preparation of cells [as an outgrowth from biopsies (explants)
or isolated into a single-cell suspension] and the use of growth
factors alone or from feeder cells (e.g. 3T3 fibroblasts) are exam-
ined as conditions that promote LEC growth and progenitor
phenotype [5]. LEC culture on intact (iAM) or devitalised and/
or denuded (dAM) AM and exposure of cultivated LEC to the air–
liquid interface (air-lifting) are also studied to develop methods
that maintain LEC stemness and stratification, respectively [5].
Furthermore, studies are underway to modify the structure of AM
to enhance the ability of this substrate to support the expansion of
LEC [10].
Key problems encountered with LSCD therapy that limit ther-
apeutic outcomes include: (i) variations in treatment outcomes
due to structural heterogeneity of AM scaffolds and differences in
the severity of LSCD, (ii) a poor understanding of mechanisms
underlying corneal repair mediated during LSCD therapy, (iii)
limited supplies of donor tissue which is essential in cases of
bilateral total LSCD and (iv) inadequate means for eliminating
long-term immunosuppression that is necessary following trans-
plantation of allogeneic sources of LEC.
Solutions proposed for these challenges include: (i) the use of
alternative cell types, corneal prostheses and cell storage strategies
to alleviate problems with limbal tissue availability, (ii) the use of
structurally uniform biomaterials for the delivery of LEC to the
damaged ocular surface to eliminate variations in LSCD treatment
and (iii) the use of biomaterials with well-characterised and easily
modified structures to understand mechanisms by which LEC
reverse the symptoms of LSCD.80 www.drugdiscoverytoday.comBiomaterials for regeneration of the cornea
The main uses for biomaterials applied to reconstruction of
damaged corneal epithelium include hydrogels for LEC delivery
[11–19], bioengineered prosthetic devices (keratoprostheses: KPro)
that replace dysfunctional corneal tissue [20–26], contact lenses
used as ocular bandages or for the correction of refractive errors
[27–29], and materials for transcorneal drug delivery [30–34].
Ocular biomaterials used for the fabrication of intraocular lenses,
glaucoma filtration implants, scleral buckles and viscoelastic repla-
cement agents are reviewed elsewhere [35] and will not be dis-
cussed in this article. The wide range of biomaterials currently in
use for regeneration of the cornea includes hydrogels [11–
19,36,37], porous silk fibroin films [38], keratin from hair or wool
[39], 3D nanofibre scaffolds fabricated from polyamide 6/12 (PA6/
12) [40] and electrospun poly(lactide-co-glycolide) membranes
[41].
Structural modification of biomaterials to enhance LEC adhe-
sion [42,43] and control the differentiation [44] of these cells is
the current direction for the application of these tools. Corneal
epithelial tissue grown on polycarbonate surfaces with pore
diameters of 0.1–3.0 mm were shown to lay down continuous
BM and a regular pattern of hemidesmosomal plaque on a 0.1 mm
surface, and no adhesive structures assembled on a nonporous or
3.0 mm surface [42]. On hydroxyethylmethacrylate (HEMA)
hydrogels modified by the addition of amines (N,N-dimethyla-
minoethylmethacrylate) or carboxyl moieties (methacrylic acid),
the expression of adhesion receptors, integrin a6 and b4 in
corneal epithelial cells was shown to be higher on surfaces
containing amine moieties than on surfaces containing only
carboxyl moieties [43]. Furthermore, modification of the stiff-
ness of collagen gels was recently shown to direct LEC differ-
entiation [10,44].
The integration of a range of compatible biomaterials with com-
plementary functions for the construction of artificial systems may
lead to the development of sophisticated medical devices with the
potential to considerably enhance the efficacy and predictability of
LSCD therapy. Those systems may be designed specifically to treat
the differing extents of LSCD, with combined delivery of drug and
cell therapies. Hydrogels, in particular, present key properties which
indicate their suitability for the culture and/or delivery of LEC (i.e.
chemical inertness, uniformity of structure, biocompatibility, and
mechanical strength and pliability).
Hydrogels for the design of corneal prosthetics are also becom-
ing increasingly popular. Collagen [20–26] and poly(2-hydro-
xyethyl methacrylate) (PHEMA) [45] gels are mainly applied to
the construction of KPro that are biointegrable in a manner that
promotes regeneration of corneal cells, nerves, and extracellular
matrix (ECM). In our own laboratory we have characterised lami-
nin-coated, plastically compressed collagen gels containing cor-
neal fibroblasts suitable for the delivery of LEC to the damaged
cornea (Fig. 2) [24–26].
In this article we highlight several well-established and emer-
ging hydrogel systems and discuss their suitability for treating
LSCD.
The potential for the use of hydrogels in LSCD therapy
Hydrogels are multi-component systems consisting of a 3D net-
work of polymer chains and water [46]. Physical gels (pseudogels)
Drug Discovery Today  Volume 18, Numbers 1–2  January 2013 REVIEWS
Compressed collagen
hydrogel
Collagen gel plastic
compression
120 grams 5′′
LEC culture on a
compressed collagen gel CK3 and CK14 in LECs
on compressed collagen
A
B
Drug Discovery Today 
FIGURE 2
The use of a compressed collagen hydrogel for ex vivo expansion of limbal epithelial cells. Collagen is plastically-compressed using a 120 g load. CK3 (A) and CK14
(B) are expressed in LEC (green) expanded on a laminin-coated compressed collagen gel embedded with keratocytes. Cell nuclei are stained with propidium
iodide (red). Images represent 3 different experiments from 3 different corneoscleral rims. Scale bar: 50 mm. Reproduced from ref. [24].
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static forces, hydrogen bonds, hydrophobic interactions or chain
entanglements, and in chemical hydrogels, covalent bonds link
polymer chains. Hydrogels are attractive scaffolding materials
owing to their highly hydrated network structure, which enables
encapsulation of cells and bioactive molecules, and efficient mass
transfer of soluble factors to and from immobilised cells [46].
Clinical and pre-clinical studies indicate that fibrin, collagen,
silicone, alginate, chitosan and gelatin hydrogels are lead candi-
dates for the treatment of LSCD (Table 1).
Fibrin hydrogels
Fibrin gels are prepared by the combination of fibrinogen and
thrombin, or from autologous serum [47]. These hydrogels are
used extensively as biopolymer scaffolds to regenerate adipose
tissue, bone, cartilage, cardiac tissue, liver, nervous tissue, ocular
tissue, skin, tendons and ligaments [47]. Certainly, the use of fibrin
hydrogels in LSCD therapy is already established [11–15].
Previous reports demonstrated that the majority of individuals
within a group presenting LSCD regained their vision following
treatment with fibrin-cultured LEC, and this outcome was sus-
tained over long-term periods [12,13]. Rama et al. [1,12] reported a
study where 14 out of 18 patients treated with LEC cultured on
fibrin gels rapidly regained useful visual acuity. The corneas of
treated patients underwent re-epithelialisation within the first
week, inflammation and vascularisation was reduced within the
first three to four weeks, and at a 12–27 month follow-up, corneal
surfaces were clinically and cytologically stable [12].
Subsequent studies demonstrated that fibrin gels were capable
of supporting the stem and/or progenitor phenotype of LEC
[13,14]. These gel scaffolds preferentially cultivated the expansion
(ex vivo) of LEC; subcultivation of limbal holoclones preservedstem and progenitor cells in the basal layer of fibrin-based epithe-
lial sheets [14]. Furthermore, the generation of normal, renewing
epithelium on donor stroma treated with fibrin-cultured LEC
correlated with cultures in which p63 bright cells constituted
more than 3% of the total number of clonogenic cells [13]. The
majority (78%) of LSCD patients treated with fibrin-cultured LSC
containing 3% p63 bright cells were successfully treated, whereas
only 11% of LSCD patients received viable treatment with cultures
containing 3% p63 bright cells [13].
Interestingly, another progenitor cell type, mesenchymal stem
cells (MSCs), encapsulated in fibrin gels induced reconstruction of
the damaged corneal surface, and these cells expressed the corneal
epithelial cell specific marker, cytokeratin 3 (CK3) when they were
transplanted [15]. Further investigation under in vitro conditions
demonstrated that MSCs co-cultured with LEC or LEC conditioned
medium, rapidly differentiated into cells that were phenotypically
and morphologically similar to corneal epithelial cells [15]. These
results are supported by a recent report demonstrating that MSCs
reside in the limbal niche [48].
Therefore, fibrin hydrogels are clearly capable of maintaining
the phenotype and directing the fate of stem cells, indicating that
they may be exploited to understand the fundamental biology of
LSC differentiation and self-renewal. The positioning of limbal
holoclones on fibrin-cultured epithelial cells [14] suggests that
these biomaterials may be used to construct a niche-like environ-
ment for LSC. Certainly, there is considerable potential to begin
understanding mechanisms that regulate LSC function during
transplantation, using these gels as in vitro systems. The require-
ment for effective logistics to deliver LSCD therapy together with
the practicality of fibrin-cultured LEC, suggest that this hydrogel
can form part of cell preservation and transportation technologies
for wide ranging applications in corneal reconstruction therapies.www.drugdiscoverytoday.com 81
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TABLE 1
A summary of hydrogels at the clinical and pre-clinical stages of therapy for corneal regeneration
Hydrogel Description Ocular use Clinical success Refs
Fibrin Fibrin hydrogels are composed of a cross-linked fibrin
network either formed by the combination of fibrinogen
and thrombin, or isolated from autologous serum.
Ex vivo expansion of LESC
and encapsulation
of MSC for treating LSCD.
LSCD symptoms were reversed in
human patients and animal models
of LSCD.
[11–15]
Plastically compressed
collagen
Collagen is an ECM protein. Conventional collagen gels
are inherently weak due to high water content. Therefore,
they are plastically compressed to achieve a stronger gel by
expelling water.
LEC culture for application
to construction of an
artificial cornea.
N/A. [16,24–26]
EDC and NHS cross-linked
recombinant human collagen
N/A. Corneal epithelial cell culture. Tested on humans in a Phase
1 clinical trial.
[22]
Recombinant human
collagen-phosphorylcholine
(RHCIII-MPC) hydrogels
Biosynthetic implants were fabricated from freeze-dried recombinant
human collagen type III (RHCIII), either with or without the
incorporation of 2-methacryloyloxyethyl phosphorylcholine (MPC).
Corneal substitute. Promoted cell and nerve repopulation and
enhanced resistance to neovascularisation
in alkali-burned rabbit eyes.
[20]
Hydrated collagen and
N-isopropylacrylamide
copolymer-based ECMs
Gels were grafted with the laminin adhesion pentapeptide
motif, YIGSR.
Keratoprosthesis or
artificial cornea.
Successful in vivo regeneration of host
corneal epithelium, stroma, and functional
nerves in pig models.
[21]
Silicone Silicone hydrogels are polymers composed of carbon,
hydrogen and oxygen.
Soft contact lens, ocular bandage
for treating persistent epithelial
defects (PED) and substrate for
LEC culture.
Silicone contact lens can deliver LEC to
the cornea and relieve PED symptoms
in humans.
[29,30]
Alginate Alginate is a polysaccharide. Alginate hydrogels comprise
blocks of mannuronic and guluronic acid cross-linked
via carboxyl groups with multi-valent cations.
LEC storage. N/A. [59]
Alginate microspheres
incorporated into
collagen hydrogels
N/A. Drug delivery and LEC culture. N/A. [31]
Chitosan Chitosan is a polysaccharide. Hydrogels are produced
through cross-linking chitosan using glutaraldehyde,
rutin or light.
LEC culture and ocular
drug delivery.
Decreased ocular drug elimination time. [19,30,32]
Chitosan membranes modified
with poly-D,L-lactic acid (PDLLA)
N/A. Ocular bandage. Promoted wound healing in
animal models of LSCD.
[37]
Chitosan hydrochloride (CH/HCl) N/A. Ocular drug delivery. Increased transcorneal penetration
of ocular drugs.
[33]
(PDLLA/chitosan) membranes Poly-D,L-lactic acid (PDLLA) was modified with chitosan. Corneal wound healing. Promoted wound healing of alkali-burned
corneas in vivo and decreased scar tissue
formation in rabbit models.
[34]
Gelatin Partially hydrolysed collagen. Corneal endothelial and stromal cell
culture, and ocular drug delivery.
Supports stromal regeneration
in animal model.
[62–67]
GelfoamW Gelatin sponge. Ocular drug delivery. Increases drug-release time. [73,74]
Poly(2-hydroxyethyl methacrylate)
(PHEMA) hydrogels
PHEMA gels are produced by mixing 2-hydroxyethyl
methacrylate (HEMA) in the presence of water
(HEMA/water ratio 20/80 w/w), 0.1 wt% (of monomer)
cross-linking agent, and 0.12 wt% (of monomer) initiators
(ammonium persulphate and tetramethylethylenediamine).
Keratoprosthesis or artificial cornea. Supports corneal wound healing
in animal models.
[45]
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Collagen is the most abundant structural protein in the cornea,
and is biocompatible, biodegradable, possesses low immunogeni-
city and can maintain LEC adhesion, proliferation and differentia-
tion [20–26]. The BM of the limbal epithelium contains type IV
collagen (a1 and a2 chains) as well as type IV collagen (a3 chain),
and type V collagen is present in the corneal BM [49]. At present,
collagen hydrogels are mainly applied to LEC culture [16] and the
formation of tissue-engineered scaffolds or KPro used for replace-
ment of corneal tissue [20–26].
Magnetically oriented collagen fibre scaffolds were recently
applied to the regeneration of human hemi corneas in vitro [23].
Reconstruction of the hemi cornea involved the formation of a
well-defined epithelium as well as stroma by keratocytes which
when aligned with collagen, were shown to lay down ECM com-
ponents with features typical of collagen fibrils [23]. The aligned
collagen and/or keratocyte construct induced re-epithelialisation
of corneal stroma in vivo in a rabbit corneal injury model [23],
indicating the potential of this biologically functional medical
device for treating LSCD.
By contrast, conventional collagen hydrogels are plastically
compressed or chemically cross-linked to enhance mechanical
strength before their use in the formation of stratified LEC
[16,24–26]. This strategy is in development at present, to design
corneal equivalents for application as biointegrable KPro.
1-Ethyl-3-(3-dimethyl aminopropyl) carbodiimide (EDC) and
N-hydroxysuccinimide (NHS) cross-linked recombinant human
collagen-based artificial corneas are one of the first examples of
these constructs tested on humans. In a Phase I clinical trial, this
biosynthetic scaffold was transplanted to the damaged cornea of
ten patients with vision loss [22]. Six-month postoperative results
demonstrated the regeneration of host epithelium and the
growth of stromal cells into the implant, and a 24-month fol-
low-up report of this study showed that implants retained stabi-
lity and remained avascular without prolonged use of steroid
immunosuppression, commonly required in traditional allo-
transplantation. Corneal re-epithelialisation, tear film formation,
stromal cell maturation and nerve regeneration was observed in
all patients and after 24 months, vision was significantly
improved in six patients [22]. This study was promising because
it indicated that collagen KPro can be applied as donor corneas in
a clinical setting.
Simultaneous use of collagen hydrogels as corneal tissue repla-
cements and as delivery systems for LEC may lead to the devel-
opment of KPro capable of treating LSCD.
Silicone hydrogels
Silicone hydrogels comprise lotrafilcon A, balafilcon A, senofilcon
A and comfilcon A, and are mainly used to produce second
generation, soft contact lenses for the correction of refractive
errors and as ocular bandages which aid re-epithelialisation of
the cornea [27]. The major advantage of silicone lenses is efficient
transmission of oxygen to the ocular surface using its water and
polymer content [27]. Highly oxygen-permeable (Dk) silicone
hydrogel lenses enable rapid and stable re-epithelialisation of
the cornea, have eliminated lens-induced hypoxia for the majority
of wearers and have a less pronounced detrimental effect on
corneal homeostasis compared to other lens types [28].Recent reports suggest that in addition to application as a visual
aid and an ocular bandage, silicone hydrogels may be applied to
LSCD therapy [29,30]. The treatment of persistent corneal defects
(PED), which include LSCD, dry eye syndrome, graft-versus-host
disease, toxic keratitis, limbic keratoconjunctivitis, and neuro-
trophic keratitis [29], with hydrogel contact lenses (i.e. silicone
lenses) is well-documented [27–30]. Moreover, lotrafilcon A con-
tact lenses were reported to sustain proliferation and migration of
LEC from limbal tissue, which displayed a corneal phenotype
(CK3+/CK12+/CK19+) and expressed p63 [30]. Microvilli with
adhesive projections were observed on the apical surface of LEC
cultured on the lens indicating that these cells were stable and
likely to survive long-term [30]. Therefore, these findings sug-
gested that it may be possible to generate a corneal epithelium
on silicone contact lenses and easily transfer this to cornea pre-
senting LSCD.
Despite the therapeutic benefits of silicone lenses for PED and
LSCD, further research is needed to improve the biocompatibility
of this biomaterial. The high modulus (silicone hydrogels are
stiffer and less flexible than conventional hydrogels) of these
lenses causes mechanical interaction with ocular tissue which lead
to papillary conjunctivitis and disruption of the tear film structure
[27]. Furthermore, the high oxygen permeability of silicone lenses
induces epithelial inclusions related to mucin ball formation [50].
The development of silicone contact lens systems for the expan-
sion and delivery of LEC will therefore require investigations into
structural modifications (i.e. alterations to modulus and Dk) of this
hydrogel which favourably complement corneal homeostasis and
physiology.
Alginate hydrogels
Alginates are polysaccharides found in brown algae and bacteria,
consisting of unbranched binary co-polymers of 1–4 linked b-D-
mannuronic acid and a-L-guluronic acid, which when cross-linked
by multi-valent cations (e.g. Ca2+, Ba2+, La3+, Fe3+, Zn2+, Mg2+, Sr2+)
form into gels [50]. Alginate hydrogels are one of the most well-
characterised cell immobilisation substrates [51,52] due to effec-
tive immunoisolatory and mass transfer properties [50], and are
widely used as biomaterial tools in the field of regenerative med-
icine [53–55].
The use of alginate hydrogels for ocular therapy is relatively
novel. Only a small number of studies have been performed to
examine the manner that alginate may be applied for ocular
reconstruction. Alginate microspheres incorporated into collagen
hydrogels were previously demonstrated as a viable composite
construct for controlled drug delivery as well as human corneal
epithelial cell growth [31]. Alginate membranes coated with chit-
osan used as base matrices for LEC cultivation maintained the
attachment, spreading and growth of these cells [18]. Another
composite hydrogel containing sodium alginate dialdehyde and
hydroxypropyl chitosan was used for transplantation of corneal
endothelial cells (CEC) onto Descemet’s membrane, and demon-
strated that encapsulated CEC remained viable and retained their
normal morphology [56].
These preliminary studies have highlighted the potential of
alginate gels as culture systems for LEC. Because the structure of
alginate gels can be modified to direct cell phenotype, particularly
stem cell differentiation [57,58], and enhance cell survival, thiswww.drugdiscoverytoday.com 83
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FIGURE 3
Alginate gels as LEC storage devices. Calcium alginate gel discs (a) with dimensions approximately 19 mm in length and 1.5 mm in depth are viable storage
modules for LEC. Images (100 magnification) represent three individual experiments. Data points on bar chart (b) represent the mean (n = 3  S.E.M.) number of
live cells extracted from alginate gel discs following 1, 3, 5 and 7 day culture periods.
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developed for application to reversing the pathology of LSCD.
Moreover, the well-reported use of alginate gels for cell preserva-
tion [59,60] will allow this hydrogel to be developed into a trans-
port and/or storage medical device (Fig. 3) applicable to corneal
cell-based therapies.
Chitosan hydrogels
The mucoadhesive polysaccharide, chitosan is biocompatible,
biodegradable and displays unique haemostatic activity and
wound-healing properties that makes it attractive for use in bio-
medical applications [19]. Chitosan alone was previously applied
topically to the eyes of rabbits to repair the endothelium after they
had sustained central corneal wounds, because these polymers
were indicated to induce regeneration of vascular endothelium
[36].
Synthetic chitosan membranes supported the viability and
growth of corneal epithelial cells in a manner comparable to
AM [19]. This study was supported by another report showing
that chitosan membranes modified with poly-D,L-lactic acid pro-
moted wound healing of alkali-burned corneas in vivo and
decreased scar tissue formation [37]. These findings are particu-
larly exciting because one of the major advantages of AM is its
anti-scarring abilities. Therefore, chitosan may be a substitute for
AM.
The well-characterised abilities of chitosan for ophthalmic drug
delivery may be exploited together with the capacity of this
polymer for cultivation of corneal epithelial cells. Chitosan poly-
mers can increase precorneal drug residence times to slow down
drug elimination by the lacrymal flow, by increasing solution
viscosity and by interacting with the negative charges of the
mucus [30]. Chitosan nanoparticles are also able to enhance the
therapeutic index of clinically challenging drugs [32]. Chitosan
hydrochloride increased transcorneal penetration of topically
applied ofloxacin and the therapeutic efficacy of this ophthalmic
drug [33]. Furthermore, a novel copolymer, poly(N-isopropylacry-
lamide)-chitosan, was previously suggested as a potential thermo-
sensitive in situ gel-forming material for ocular drug delivery [34].
Chitosan hydrogels may therefore be used to create a device
which delivers both LEC and ocular drugs that enhance the effects
of these cells, thus constituting a novel strategy to treat LSCD.84 www.drugdiscoverytoday.comGelatin hydrogels
Gelatin is a mixture of peptides and proteins produced by acid and
alkaline processing (partial hydrolysis) of collagen extracted from
skin, bone and connective tissue [61]. Currently, gelatin hydrogels
are under development as substrates for CEC and stromal cell
culture, but they have not been used as supports for cultivating
LEC. These gels have received the most attention for ocular use as
drug delivery vehicles.
The success of gelatin gels for the culture of CEC and stromal
cells indicate that LEC may be well-supported by these scaffolds.
Gelatin gels were previously shown to provide stable mechanical
support for CEC sheets [62], enabling expression of typical markers
for these cells [zonula occludens-1, Na+/K+-ATPase, and N-cad-
herin] [63]. Porous gelatin was demonstrated as suitable for the
engineering of corneal stroma [64].
Soluble ocular drug insert matrices comprised of raw gelatin [65–
68] or chemically modified [69,70] and composite gelatin [71,72]
gels also indicate the feasibility of these biomaterials for LEC culture.
Gelatin gels cross-linked with EDC were shown to support the
culture of iris pigment epithelial cells more efficiently than gels
cross-linked with glutaraldehyde [69]. A cationised gelatin film with
incorporated epidermal growth factor (EGF) resulted in a reduction
in an epithelial defect in rabbit corneas; this was accompanied by
significantly enhanced epithelial proliferation compared with the
reduction observed with topical application of EGF solution or the
placement of an EGF-free gelatin film [65]. Polyvinyl alcohol (PVA)–
gelatin polymeric blends are also promising as ocular inserts for
prolonged release of antibiotics in the eye [71].
The absorbable gelatin sponge, Gelfoam1, is a manufactured
drug carrier for either local or systemic drug delivery through the
ophthalmic route. This eye medical device was reported to prolong
the activity of the insulin through gradual release aided by the
slow and constant tear production from the lachrymal system [73].
Another study showed that dilation of the pupil induced by
phenylephrine and tropicamide delivered using Gelfoam1 was
greater and longer lasting than that produced by eyedrops with an
equivalent amount of these drugs [74]. As Gelfoam1 can be worn
with contact lenses, in a hydrated form; this hydrogel as well
as other gelatin hydrogels may serve as a growth factor and/or
drug-release feeder device to maintain LEC delivered to the ocular
surface using silicone lenses.
Drug Discovery Today  Volume 18, Numbers 1–2  January 2013 REVIEWS
R
ev
ie
w
s
 P
O
S
T
S
C
R
E
E
NEmerging hydrogel systems
Hydrogels at the early experimental stage before application as
substitutes for AM include hyaluronic acid (HA) [75] gels, thermo-
sensitive gels (e.g. Mebiol1) [76,77], poly(2-hydroxyethyl metha-
crylate (PHEMA) [78–80] and PVA [81,82] gels that are established
as component parts of the artificial cornea, as well as muscle-
derived myogel [83].
HA gels chemically cross-linked with poly(N-2-hydroxyethyl)
(2-aminoethylcarbamate)-D,L-aspartamide (PHEA-EDA) were pre-
viously suggested as a suitable material for the release of limbal
cells for corneal regeneration [75]. HA and/or PHEA-EDA films
enabled moderate and/or poor adhesion of human corneal epithe-
lial cells, rabbit limbal epithelial cells and fibroblasts. Contact
lenses coated in their inner surface with the HA/PHEA-EDA film
enabled greater cell adhesion, but this was transitory; viable cells
were released after three days [75]. Therefore, HA and/or PHEA-
EDA hydrogels were suggested as suitable for delivering limbal cells
to treat corneal damage.
The thermosensitive, synthetic polymer gel, Mebiol1 was pre-
viously reported as capable of supporting LEC and maintaining the
stem phenotype of these cells. Mebiol1 supported limbal explant
proliferation and LEC cultured on this gel expressed LSC markers
(ATP-binding cassette sub-family G member 2 and p63), transient
amplifying cell markers (connexin 43, integrin a9) and cornea
differentiation marker (CK3) [76]. The transplantation of autologous
LEC grown in Mebiol1was shown to restore a nearly normal ocular
epithelial surface in eyes with unilateral LSCD in rabbit models [77],
indicating that this hydrogel is almost at the pre-clinical stage.
By contrast, PHEMA sponges used to construct the porous skirt
material in the Chirila KPro require improvements in biocompat-
ibility [78–80], to prevent calcification and proangiogenic effects
before they can be developed into a viable substrate for LEC.
Another biomaterial component of the artificial cornea, the por-
ous nano-hydroxyapatite and/or poly (vinyl alcohol) hydrogel
[81], may also be suitable for LEC culture; this material was
demonstrated to support the maintenance and growth of corneal
epithelium in vitro [82].The novel muscle-derived hydrogel, myogel [83] may also pro-
vide an alternative cell (ex vivo expanded cells) carrier for LSCD
with a further reduction in risk, as it is derived from an autologous
muscle biopsy.
Concluding remarks
We have already crossed the threshold for major change in LSCD
therapy from conventional AM-based methodologies to more
versatile and practical methods involving natural and synthetic
biomaterial systems.
Fibrin and collagen hydrogels have developed beyond the pre-
clinical stage, and they are currently proven as viable for the
treatment of LSCD and as corneal prosthetics, respectively. Other
hydrogels present unique properties including intrinsic anti-scar-
ring capabilities (chitosan), efficient mass transfer abilities (algi-
nate, gelatin, silicone) and properties appropriate for tissue
engineering (alginate), which indicate them as excellent candi-
dates for the treatment of LSCD.
The structures of ‘clean’ hydrogel systems may be manipulated to
alter their physical and chemical properties, internal porosity, and
surface topography to induce predictable changes in cell behaviour.
Therefore, these biomaterials applied to the treatment of LSCD may
potentially enable a more in-depth understanding of the mechan-
isms underlying the reversal of pathological symptoms of this dis-
order, which may introduce a novel field of ophthalmic medicine.
We conclude that given the considerable body of evidence
demonstrating the efficacy of hydrogels in reconstruction of the
damaged cornea, AM can certainly be replaced or complemented
with these biomaterials for the treatment of LSCD.
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